Recognized standard
M24 3rd Edition
FDA recognition 7-288 · CLSI · InVitro Diagnostics
Key facts
| Recognition number | 7-288 |
|---|---|
| Designation | M24 3rd Edition |
| Title | Susceptibility Testing of Mycobacteria, Nocardiae and other Aerobic Actinomycetes |
| Standards developer | Clinical Laboratory Standards Institute |
| Specialty area | InVitro Diagnostics |
| Date of entry | Jul 15, 2019 |
| Device classes | Class 2 |
| Scope (excerpt) | This standard provides protocols and related quality control parameters and interpretive criteria for the susceptibility testing of mycobacteria, Nocardiae spp. and other aerobic actinomycetes. |
At a glance
- 1–9 Product codes
- 1–9 FDA guidance documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-recognized consensus standards
The FDA recognizes voluntary consensus standards that manufacturers can cite in premarket submissions to show conformity with specific requirements.
Source: U.S. Food and Drug Administration (FDA), Recognized Consensus Standards database · Source date: